NYSE · BHV
Financial Services · Asset Management - Bonds
$12.39
Up+$0.28 (+2.26%)
Updated Sep 14, 2026, 11:12 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BHV closed at $12.39 after 19 trading sessions, down 3.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $12.72 | $12.72 | $12.39 | $12.39 | 955.14 |
| Sep 10, 2026 | $12.36 | $12.7099 | $12.22 | $12.49 | 10.47K |
| Sep 9, 2026 | $12.46 | $12.61 | $12.46 | $12.47 | 1.95K |
| Sep 8, 2026 | $12.48 | $12.5037 | $12.48 | $12.5037 | 952.9 |
| Sep 4, 2026 | $12.47 | $12.72 | $12.47 | $12.47 | 974.63 |
| Sep 3, 2026 | $12.55 | $12.68 | $12.45 | $12.57 | 6.46K |
| Sep 2, 2026 | $12.70 | $12.70 | $12.49 | $12.57 | 4.89K |
| Sep 1, 2026 | $12.72 | $12.72 | $12.46 | $12.58 | 2.86K |
| Aug 31, 2026 | $12.51 | $12.715 | $12.51 | $12.61 | 3.63K |
| Aug 28, 2026 | $13.02 | $13.02 | $12.45 | $12.7166 | 6.12K |
| Aug 27, 2026 | $12.92 | $12.92 | $12.4501 | $12.59 | 3.94K |
| Aug 26, 2026 | $12.51 | $12.715 | $12.51 | $12.56 | 4.53K |
| Aug 25, 2026 | $12.80 | $12.80 | $12.643 | $12.71 | 4K |
| Aug 24, 2026 | $12.56 | $12.7099 | $12.56 | $12.65 | 3.68K |
| Aug 21, 2026 | $12.45 | $12.52 | $12.45 | $12.52 | 5.5K |
| Aug 20, 2026 | $12.51 | $12.78 | $12.51 | $12.51 | 3.39K |
| Aug 19, 2026 | $12.60 | $12.60 | $12.60 | $12.60 | 120.63 |
| Aug 18, 2026 | $12.54 | $12.54 | $12.54 | $12.54 | 208.63 |
| Aug 17, 2026 | $12.68 | $12.80 | $12.68 | $12.80 | 1.4K |
The latest Smart Investors Daily articles mentioning BHV.
BHV research
Company profile and research snapshot.
Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Feb 4, 2026
Municipal bond closed-end funds (CEFs) are seeing narrowing discounts, with NXP and MHF offering the most compelling value in the space at present. Read the full analysis here.
prnewswire.com · Dec 11, 2025
In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer There were low rates of adverse events attributed to unconjugated payload such as hematological toxicities and diarrhea, and there were no cases of interstitial lung disease, showing a differentiated safety profile of BHV-1510 from other Trop2 ADCs BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates encouraging early clinical activity and favorable safety profile in a Phase 1 study in combination with the anti-PD-1 cemiplimab LONDON and NEW HAVEN, Conn. , Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BHV.
